Drugs / standard heparin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05984537 Comparator | Jul 2023 → Dec 2025 overdue | coronary microvascular disorder | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | standard heparin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05984537 ↗ |
| Route | Intravenous | “Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.” NCT05984537 ↗ |